1. Pleiotropic Effects of Metformin on Cancer.
- Author
-
Schulten HJ
- Subjects
- Animals, Antineoplastic Agents pharmacokinetics, Antineoplastic Agents therapeutic use, Cell Proliferation, Drug Screening Assays, Antitumor, Gluconeogenesis drug effects, Humans, Metformin pharmacokinetics, Metformin therapeutic use, Models, Molecular, Neoplasms drug therapy, Neoplasms metabolism, Antineoplastic Agents pharmacology, Metformin pharmacology, Neoplasms pathology
- Abstract
Metformin (MTF) is a natural compound derived from the legume Galega officinalis . It is the first line antidiabetic drug for type 2 diabetes (T2D) treatment. One of its main antidiabetic effects results from the reduction of hepatic glucose release. First scientific evidence for the anticancer effects of MTF was found in animal research, published in 2001, and some years later a retrospective observational study provided evidence that linked MTF to reduced cancer risk in T2D patients. Its pleiotropic anticancer effects were studied in numerous in vitro and in vivo studies at the molecular and cellular level. Although the majority of these studies demonstrated that MTF is associated with certain anticancer properties, clinical studies and trials provided a mixed view on its beneficial anticancer effects. This review emphasizes the pleiotropic effects of MTF and recent progress made in MTF applications in basic, preclinical, and clinical cancer research.
- Published
- 2018
- Full Text
- View/download PDF